One of the objectives of the dose expansion was to assess the antitumor activity of AMG 232 among patients not only with P53WT tumors but also among those with MDM2 amplification and MDM2 overexpression, which is common in liposarcomas, GBM, breast cancer, and multiple myeloma [5–11] Per local evaluation, no objective response were observed. Here, MDM2 is linked to plasma cell myeloma.